The CHK1 inhibitor prexasertib in BRCA wild-type platinum-resistant recurrent high-grade serous ovarian carcinoma: a phase 2 trial.
Giudice E, Huang TT, Nair JR, Zurcher G, McCoy A, Nousome D, Radke MR, Swisher EM, Lipkowitz S, Ibanez K, Donohue D, Malys T, Lee MJ, Redd B, Levy E, Rastogi S, Sato N, Trepel JB, Lee JM.
Giudice E, et al. Among authors: huang tt.
Nat Commun. 2024 Mar 30;15(1):2805. doi: 10.1038/s41467-024-47215-6.
Nat Commun. 2024.
PMID: 38555285
Free PMC article.
Clinical Trial.